glycyrrhizin
biolog
activ
compound
isol
liquoric
root
use
treatment
chronic
hepat
examin
involv
matrix
metalloproteinas
mmp
develop
lipopolysaccharid
lp
dgalactosamin
galn
induc
liver
injuri
mice
also
investig
effect
glycyrrhizin
express
model
level
serum
alanin
aminotransferas
alt
aspart
aminotransferas
ast
increas
lp
galn
treatment
express
mrna
protein
markedli
upregul
liver
tissu
h
lpsgaln
treatment
pretreat
glycyrrhizin
mg
kg
mmp
inhibitor
mg
kg
suppress
increas
serum
level
alt
ast
mice
treat
lpsgaln
furthermor
glycyrrhizin
inhibit
level
mrna
protein
immunohistochem
reaction
observ
macrophagesmonocyt
infiltr
inflammatori
area
liver
injuri
glycyrrhizin
reduc
infiltr
inflammatori
cell
immunoreact
liver
injuri
result
indic
play
role
develop
lpsgalninduc
mous
liver
injuri
suggest
inhibit
glycyrrhizin
acut
liver
injuri
may
due
downregul
demonstr
produc
mmp
knittel
et
al
liver
injuri
recent
increas
activ
liver
report
involv
anim
hepat
model
wielockx
et
al
ito
et
al
ito
et
al
studi
examin
involv
lp
galninduc
mous
liver
injuri
effect
glycyrrhizin
express
model
studi
perform
accord
guid
principl
care
use
laboratori
anim
approv
japanes
pharmacolog
societi
ethic
committe
anim
experi
tsurumi
univers
school
dental
medicin
sixweekold
male
balbc
mice
g
japan
slc
hamamatsu
japan
kept
environment
control
room
humid
allow
free
access
food
water
lp
escherichia
coli
galn
purchas
sigma
st
loui
mo
drug
dissolv
pyrogenfre
salin
inhibitor
amino
acid
purchas
calbiochem
san
diego
ca
recombin
mous
fluorogen
peptid
substrat
obtain
r
system
minneapoli
mn
usa
glycyrrhizin
prepar
medicin
chemistri
research
depart
minophagen
pharmaceut
co
ltd
puriti
glycyrrhizin
use
studi
approxim
ph
solut
includ
glycyrrhizin
adjust
use
naoh
liver
injuri
induc
intraven
inject
mixtur
ng
lp
mg
galn
per
mous
h
lpsdgaln
treatment
mice
anaesthet
diethyl
ether
collect
blood
heart
punctur
hepatocelluar
damag
evalu
measur
serum
alt
ast
use
spot
chem
analys
arkray
kyoto
japan
intraperiton
administr
glycyrrhizin
inhibitor
perform
min
lpsgaln
treatment
respect
control
mice
receiv
salin
effect
test
compound
liver
damag
examin
h
lpsgaln
treatment
liver
remov
anim
frozen
immedi
liquid
nitrogen
total
rna
extract
frozen
liver
acidguanidinephenolchloroform
method
use
isogen
nippon
gene
toyama
japan
cdna
revers
transcrib
total
rna
use
rnapcr
kit
takara
biomed
shiga
japan
serv
templat
pcr
pcr
reaction
perform
use
ex
taq
takara
japan
synthet
forward
primer
aga
aca
cca
tcg
aga
cc
revers
primer
tca
gcg
ttc
cca
tac
tt
design
amplifi
fragment
synthet
forward
primer
cca
cca
cag
cca
act
atg
revers
primer
atg
ccg
tct
atg
tcg
tct
design
amplifi
fragment
vaillant
et
al
pcr
profil
follow
denatur
reanneal
extens
total
cycl
murin
dehydrogenas
gapdh
primer
pair
use
forward
primer
aca
gtc
cat
gcc
atc
revers
primer
cca
ccc
tgt
tgc
tgt
pair
primer
amplifi
pcr
product
bp
pcr
product
electrophores
agaros
gel
stain
sybr
gold
molecular
probe
ca
oligonucleotid
synthes
hokkaido
system
scienc
hokkaido
japan
pcr
product
amplifi
without
revers
transcript
reaction
fluoresc
intens
band
measur
atto
lane
spot
analys
atto
tokyo
japan
liver
remov
anim
frozen
liquid
nitrogen
store
assay
liver
tissu
homogen
mm
trishcl
contain
mm
monothioglycerol
homogen
sampl
centrifug
g
min
protein
concentr
measur
dc
protein
assay
reagent
bio
rad
laboratori
ca
usa
amount
liver
measur
commerci
avail
elisa
kit
r
system
mn
usa
recombin
mous
ng
activ
incub
mm
apma
paminophenylmercur
acet
h
activ
incub
mm
substrat
fluorogen
peptid
substrat
ml
tcnb
mm
trishcl
ph
mm
ccl
mm
nacl
brij
room
temperatur
min
test
compound
preincub
enzym
min
enzymat
activ
measur
fluoresc
plate
reader
excit
nm
emiss
nm
ether
narcosi
mous
liver
perfus
portal
vein
phosphatebuff
salin
pb
ph
follow
phosphatebuff
ph
paraformaldehyd
serial
cryostat
section
cut
thick
maintain
slide
coat
gelatin
use
immunohistochemistri
polyclon
antibodi
santa
cruz
biotechnolog
ca
usa
use
detect
endogen
peroxidas
block
hydrogen
peroxid
methanol
liver
section
immers
normal
rabbit
serum
pb
min
block
nonspecif
bind
primari
antibodi
ad
appropri
dilut
bovin
serum
albumin
bsa
sigma
mo
usa
pb
triton
wako
osaka
japan
incub
overnight
room
temperatur
section
incub
biotinyl
bovin
antigoat
ig
santa
cruz
biotechnolog
dilut
bsa
pb
min
room
temperatur
follow
incub
room
temperatur
peroxidaseconjug
streptavidin
dako
copenhagen
denmark
dilut
section
wash
pb
step
immunoreact
visual
use
tetrahydrochlorid
dab
sigma
hydrogen
peroxid
trishcl
buffer
ph
section
counterstain
haematoxylin
mount
specif
immunoreact
detect
control
section
without
primari
antibodi
data
shown
mean
standard
error
mean
sem
grubb
smirnov
method
use
exclud
outlier
statist
signific
differ
lpsgalntreat
group
test
group
evalu
tukeykram
multipl
comparison
test
oneway
analysi
varianc
differ
consid
signific
p
valu
less
serum
alt
ast
activ
chang
markedli
h
intraven
treatment
lpsgaln
howev
signific
increas
alt
ast
level
observ
h
figur
thereaft
increas
alt
ast
level
reduc
time
treatment
data
shown
presenc
mrna
confirm
control
liver
mrna
upregul
follow
treatment
mice
lpsgaln
signific
increas
level
mrna
observ
h
lpsgaln
treatment
figur
howev
level
mrna
increas
live
mice
treat
lpsgaln
data
shown
thu
seem
unlik
play
import
role
develop
liver
injuri
evok
lpsgaln
mice
product
slightli
increas
h
significantli
upregul
h
lpsgaln
treatment
figur
suggest
lpsgaln
induc
product
liver
howev
serum
level
detect
limit
data
shown
examin
whether
activ
involv
increas
alt
ast
level
use
inhibitor
model
pretreat
mmp
inhibitor
dosedepend
decreas
alt
ast
level
serum
h
lpsgaln
treatment
tabl
alt
ast
valu
control
mice
iu
l
respect
wherea
lpsgalntreat
mice
iu
l
respect
mmp
inhibitor
mg
kg
significantli
suppress
increas
level
alt
ast
investig
effect
glycyrrhizin
liver
injuri
induc
glycyrrhizin
mg
kg
ip
administ
mice
min
lpsgaln
treatment
glycyrrhizin
significantli
inhibit
increas
alt
ast
level
figur
valu
glycyrrhizin
lpsgalninduc
liver
injuri
mg
kg
yoshida
et
al
examin
whether
glycyrrhizin
mg
kg
ip
effect
express
mrna
liver
injuri
h
lpsgaln
treatment
express
mrna
markedli
induc
pretreat
glycyrrhizin
result
signific
inhibit
mrna
level
lpsgalntreat
liver
tissu
figur
furthermor
glycyrrhizin
significantli
decreas
level
liver
injuri
figur
howev
glycyrrhizin
direct
effect
enzymat
activ
recombin
mous
even
high
concentr
data
shown
immunoreact
predominantli
detect
pericentr
inflammatori
area
contain
mani
macrophag
neutrophil
h
lpsgaln
treatment
figur
wherea
reaction
observ
liver
nontreat
mous
figur
local
consist
macrophag
immunolabel
specif
marker
macrophag
data
shown
remark
reduc
lpsgalninjur
liver
administr
glycyrrhizin
mg
kg
ip
perform
min
lpsgaln
treatment
figur
confirm
intraven
inject
lpsgaln
caus
acut
hepat
mice
anim
model
take
advantag
abil
transcript
inhibitor
galn
potenti
toxic
effect
lp
produc
typic
apoptosi
hepatocyt
follow
fulmin
hepat
leist
et
al
liver
macrophag
kupffer
cell
stimul
lp
secret
variou
proinflammatori
cytokin
includ
tnfa
sass
et
al
tnfa
induc
apoptosi
hepatocyt
earli
stage
lpsgalninduc
liver
injuri
neutrophil
transmigr
repres
critic
step
lead
necrosi
hepatocyt
later
stage
tieg
chosay
et
al
fact
glycyrrhizin
inhibit
lp
galninduc
liver
injuri
effect
increas
serum
tnfa
level
mice
yoshida
et
al
howev
glycyrrhizin
inhibit
apoptosi
injur
hepatocyt
centrilobular
area
though
fail
prevent
caspas
lpsgalninduc
liver
injuri
ikeda
et
al
unpublish
data
total
rna
isol
liver
variou
time
treatment
lpsgaln
intens
band
shown
rel
gapdh
band
mean
sem
n
liver
remov
anim
variou
time
treatment
lpsgaln
bar
repres
mean
sem
five
six
anim
p
p
compar
valu
untreat
mice
h
test
compound
administ
lpsgaln
treatment
serum
alt
ast
examin
lpsgaln
treatment
data
express
mean
sem
five
six
anim
p
compar
valu
lpsgalntreat
mice
alt
ast
studi
express
mrna
protein
mous
liver
tissu
induc
lpsgaln
treatment
evid
involv
mmp
anim
hepat
model
wielockx
et
al
other
suggest
particip
paracetamolinduc
hepatotox
mediat
sinusoid
endotheli
cell
injuri
result
impair
microcircul
ito
et
al
ito
et
al
known
mmp
cleav
extracellular
matrix
lead
disintergr
tissu
integr
infiltr
neutrophil
macrophag
wielockx
et
al
level
mrna
protein
liver
tissu
well
serum
level
alt
ast
began
increas
h
lpsgaln
treatment
suggest
involv
develop
lp
galninduc
liver
injuri
support
find
dual
inhibitor
inhibit
increas
serum
level
alt
ast
wielockx
et
al
report
major
sourc
infiltr
cell
includ
neutrophil
macrophag
tnfagalninduc
hepat
report
consist
immunohistochem
evid
show
hepat
macrophagesmonocyt
infiltr
cell
includ
neutrophil
may
predominantli
produc
lpsgalninduc
liver
injuri
product
mmp
regul
growth
factor
cytokin
liver
knittel
et
al
mmp
specif
inhibitor
tissu
inhibitor
matrix
metalloproteinas
timp
play
essenti
role
liver
injuri
pagenstech
et
al
although
level
mrna
mrna
induc
liver
mice
treat
lpsgaln
glycyrrhizin
effect
express
data
shown
glycyrrhizin
report
prevent
antifa
antibodyand
concanavalin
ainduc
mous
liver
injuri
without
affect
cytokin
express
okamoto
kanda
okamoto
furthermor
prove
glycyrrhizin
protect
liver
variou
kind
injuri
ischaemiareperfus
hepatotox
chemic
shibayama
nagai
et
al
glycyrrhizin
also
prevent
lysi
hepatocyt
membran
induc
antiliv
cell
membran
antibodi
inhibit
elev
phospholipas
activ
shiki
et
al
report
indic
glycyrrhizin
hepatoprotect
agent
other
report
involv
pathogenesi
acut
liver
injuri
mice
sakano
et
al
man
yumoto
et
al
fact
stimul
gene
express
synthesi
tnfa
fa
ligand
sever
chemokin
nakanishi
et
al
glycyrrhizin
modul
mous
liver
injuri
evok
lpsgaln
inhibit
increas
serum
yoshida
et
al
thu
seem
glycyrrhizin
variou
mechan
liver
protect
acut
liver
injuri
includ
chemic
compoundand
druginduc
hepat
studi
glycyrrhizin
inhibit
express
mrna
encod
lpsgalninduc
liver
injuri
moreov
glycyrrhizin
reduc
inflammatori
cell
stain
liver
injuri
therefor
conceiv
glycyrrhizin
inhibit
product
prevent
signal
pathway
lead
express
mrna
process
liver
injuri
studi
also
suggest
inhibitori
effect
glycyrrhizin
liver
injuri
may
due
prevent
product
develop
acut
hepat
result
indic
product
play
role
develop
lpsgalninduc
mous
liver
injuri
suggest
hepatoprotect
effect
glycyrrhizin
may
due
downregul
infiltr
cell
liver
